VYEPTI-Ready Provider and Infusion Center Locator

Find a healthcare provider or infusion center in your area.

The data provided in connection with the VYEPTI-Ready Provider and Infusion Center Locator is for informational purposes only and based on information currently available to Lundbeck. Although facility data will be updated regularly, you should refer to an individual provider or infusion center's website for the most current information. Lundbeck does not guarantee the accuracy or completeness of any information provided herein.

No fees or other remuneration have been or will be exchanged for a provider's or infusion center's inclusion in this database. Lundbeck is not affiliated with, and inclusion in this list does not represent an endorsement of, recommendation for, or referral to the facilities contained in this database. Likewise, the facilities included do not necessarily endorse the use of any Lundbeck products.

Lundbeck makes no representations as to whether any of the sites of care contained in this database are covered by particular healthcare plans or insurers, if at all. Insurance verification is solely the responsibility of the provider. Users of this website are solely responsible for communications and interactions with any of the facilities or providers listed, and any information users send them is not governed by the Lundbeck Terms of Use and Privacy Policy. Users are responsible for compliance with state and federal laws regulating physician referrals, including state professional practice restrictions.

If you represent a provider or infusion center and would like to be removed from or added to the repository, or would like to edit existing information, please send us a request by clicking “Contact Us” at the bottom of this page. Provide the phone number and contact information of the authorized authority of the facility that can be contacted to verify the request. EPT-B-100298

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION
AND INDICATION
Contraindications

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included angioedema.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

Warnings and Precautions

Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

Adverse Reactions

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information.